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Abstract: Ulcerative colitis (UC) is the result of an inappropriate colonic inflammatory 
response triggered by environmental and genetic factors. We have recently shown that 
mucus from UC patients has a decreased phosphatidylcholine (PC) content, while clinical 
trials revealed that therapeutic addition of PC to the colonic mucus alleviated the 
inflammatory activity. The mechanisms behind this are still unclear. We hypothesized that 
PC has at least two possible functions in the intestine: First, it establishes the surface 
hydrophobicity of the mucus and therefore protects the underlying tissue against 
intraluminal aggressors; recent experiments on surgical specimens revealed reduced 
surface tension and hydrophobicity in UC patients. Second, mucus phospholipids might 
also be integrated into the plasma membranes of enterocytes and thereby influence the 
signaling state of the mucosa. PC has been shown to inhibit TNF-α induced pro-
inflammatory responses including: (1) assembly of plasma membrane actin; (2) activation 
of MAP kinases ERK and p38; and (3) activation of NF-κB and synthesis of pro-
inflammatory gene products. Other phospholipids like phosphatidylethanolamine or 
sphingomyelin  had no effect. PC also inhibited latex bead phagosome actin assembly, 
killing of M. tuberculosis in macrophages, and sphingosine-1-phosphate induced actin 
assembly in macrophages. Collectively, these results provide a molecular foundation that 
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shows PC, firstly, as an anti-inflammatory, and secondly, as a surface hydrophobicity 
increasing compound with promising therapeutic potential in the treatment of inflammatory 
bowel disease. 
Keywords:  phospholipids; phosphatidylcholine; mucosal barrier; ulcerative colitis; 
phospholipase A2  
 
1. Introduction 
A potential positive impact of phosphatidylcholine (PC) on impaired medical conditions was 
already shown in rat about 80 years ago, when Best et al. demonstrated that the supplementation of a 
fat enriched diet with PC prevented the accumulation of triglycerides in the liver of healthy rats [1]. 
Since then, increasing evidence has been obtained for the importance of PC, especially in the 
development and treatment of various pathologic inflammatory conditions.  
Quite a number of studies have concentrated on the role of PC in gastrointestinal damage and 
disease, such as the development of ulcers, bleeding and chronic inflammatory conditions like 
ulcerative colitis. However, also inflammation in other organs and tissues was shown to be influenced 
by PC: Exemplarily, oral pre-treatment with PC in a murine model of collagen-induced rheumatoid 
arthritis exhibited protective effects [2] and dietary PC ameliorated pleural inflammation in mice [3].  
Already in 1983, Lichtenberger et al. described a rat model of acid induced gastric bleeding and 
ulcer development in which the intraluminal application of a liposomal surfactant suspension acted in 
a positive manner  [4]. From this experimental outcome emerged the hypothesis of a protective 
hydrophobic and PC enriched monolayer between epithelial cells and noxious luminal compounds in 
the gastrointestinal tract (Figure 1). This went along well with the theory of a gastric mucosal barrier 
as postulated by Davenport in the 1960s. Davenport hypothesized the stomach epithelium to be 
accessible only for lipid soluble agents as opposed to electrolytes and gastric acid (reviewed by 
Lichtenberger [5]). Nowadays, the concept of gastrointestinal protection has therefore been linked not 
only to an intact mucus and enterocyte layer, but also to the presence of PC.  Int. J. Mol. Sci. 2010, 11                 
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Figure 1. Anti-inflammatory signaling by phosphatidylcholine (PC) at the mucosal barrier. 
At the mucosal gastrointestinal barrier, PC is located as firstly, luminally extended 
monolayer and, secondly, lamellar bodies within the mucus. Interaction of the inversely 
charged PC headgroups and mucins establishes a hydrophobic barrier which prevents 
invasion of bacteria through the mucus layer. PC modulates inflammatory signaling 
cascades by its integration into the enterocyte membrane. It changes the compartmentation 
of TNF receptors to lipid rafts, inhibits NF-κB activation, prevents MAP kinase 
phosphorylation and subsequent activation. The cytosolic phospholipase cPLA2α is 
activated by calcium binding which triggers its translocation to PC enriched membranes. 
Degradation of PC results in the production of LPC and arachidonic acid; the latter serving 
as an essential precursor for eicosanoid biosynthesis. Membrane binding and catalytic 
activity of cPLA2α are enhanced by MAP kinase mediated phosphorylation. PC molecules 
are shuttled within cells from the ER to plasma membranes via PC transfer proteins 
(PCTP), thus allowing the modulation of the membrane PC content. The interplay of these 
signaling events finally results in the modulation of the inflammatory response. 
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By further investigating the concept of a protective gastrointestinal mucus layer, informative results 
on the relevance of PC could be in particular obtained during in vitro and in vivo studies on the effects 
of non steroidal anti-inflammatory drugs (NSAIDs) like indomethacin and diclofenac. NSAIDs display 
a high affinity to endogenous PC and chronic application is known to induce gastrointestinal injury 
such as ulceration and bleeding as a common side effect. Secretion of NSAIDs into the bile allows the 
interaction of the drug with bile acids, thus enhancing its damaging effect. A study of the underlying 
mechanisms in cell culture and model liposomes revealed that indomethacin disturbs the lipid-lipid 
interaction in membranes and causes membrane disruption. This effect was possibly due to the drug’s 
incorporation into the membranes and was enhanced by its combination with bile acids  [6]. In fact, 
rats treated with indomethacin or diclofenac showed a reduced hydrophobicity in stomach and 
duodenum as well as a decrease in mucus PC  [7]. The combined parenteral application of 
indomethacin and PC reduced the toxic side effects on the gastrointestinal system in rodents without 
impairing the drug’s efficacy [8]. Indomethacin treatment is therefore able to alter the structure of lipid 
membranes. This has two potential effects in the GI-tract: Firstly, it reduces the mucosal 
hydrophobicity; and secondly, it most likely interacts with enterocyte membranes, which, in turn, leads 
to impairment in the function of membrane proteins and downstream signaling pathways. It is tempting 
to speculate that the addition of PC might prevent or reverse NSAID induced intestinal damage by 
being incorporated into the membrane and stabilizing membrane structures. Indeed, clinical studies 
using a PC coupled NSAID substrate reduced GI-damage without affecting its systemic effects [9,10]. 
How this concept of the protective effects of PC in the GI-tract also plays a role in the pathogenesis 
and treatment of ulcerative colitis is discussed in this review. 
2. Concept of Ulcerative Colitis 
Ulcerative colitis (UC) belongs to the group of inflammatory bowel diseases (IBD) that represents 
chronic inflammatory disorders of the intestine, generally classified by histopathological and clinical 
features into two major entities: Crohn’s disease and ulcerative colitis. While Crohn’s disease can 
occur throughout the GI-tract, most commonly in the terminal ileum and colon, inflammation in UC is 
mainly restricted to the colon  [11]. At present, the general hypothesis for the pathogenesis of 
inflammatory bowel disease is that it is a multifactorial, polygenetic disorder in which the immune 
response is triggered by luminal factors. The nature of these trigger agents is not totally clear, but, 
most likely, microbial agents have to be implicated [12]. Especially in the colon, where concentrations 
of up to one trillion microbes/mL live in a mutualistic relationship with the host, a highly effective 
defense barrier is necessary [13].  
There is increasing evidence that a loss of tolerance to the luminal microbiota is the key in 
pathogenesis of IBD: Surgical diversion of the fecal stream has been shown to resolve IBD 
inflammation distal to the surgical side  [14].  Treatment with antibiotics or probiotics has been 
successfully used in some cases [12]. Loss of immunological tolerance towards luminal commensals 
has been documented [15] and, most interestingly, in IBD the gut has lost the ability to spatially 
separate the bacteria from the apical membrane of the enterocytes. Normally, luminal bacteria in the 
gut are withheld from contact with the epithelium by an adherent mucus layer, but in UC the bacteria Int. J. Mol. Sci. 2010, 11                 
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reside directly on the luminal surface where they probably induce and maintain the inflammatory 
process [16].  
The loss of tolerance has traditionally been interpreted as a misbalanced mucosal adaptive 
immunity [17]. However, in recent years it became evident that several mechanisms that belong to the 
innate immunity are altered: The mucus layer is reduced in thickness  [18] and has an altered 
mucin [19] and lipid [20,21] composition. An altered glycosylation, sulfatation, expression of MUC2 
and localization of MUC1 have been documented [19,22]. Expression of antimicrobial or restitutional 
peptides, such as defensins [23] or trefoil factor family 3 [22], is reduced. The epithelial cell layer has 
an increased permeability  [24] and a reduced capacity for detoxification  [25]. Moreover, there are 
alterations in the mucus and fecal bacterial communities [26]. These data support the concept that UC 
is, at least in part, caused by a defect in the immediate, first line defense mechanisms that would allow 
bacteria to permanently invade the mucosa, thus enabling them to perpetuate and chronically change 
the inflammatory response. UC should therefore be classified as an “autoaggressive” rather than an 
autoimmunologic disease. Hence, successful strategies to treat such a disorder should not solely rely 
on immunosuppressive or anti-inflammatory regimens, as is the actual standard; this would target only 
the second line of reaction. Therapies should rather target the primary source of the disease, the 
impaired first line defense mechanisms. One such tool would be to reinforce the mucus layer by PC.  
As mentioned above, the first evidence that PC is indeed important for the surface integrity of the 
GI-tract came from experiments on stomach, where the pathogenesis and treatment of gastroduodenal 
ulceration were the focus of research (for review see [5] and [8]). However, the concept of a protective 
role of intestinal PC was transferred to the lower GI-tract and a protective effect of PC could be 
documented in several animal models for intestinal inflammation. PC has been shown to alleviate the 
inflammation in acetic acid  [27,28], trinitrobenzene sulfonic acid (TNBS)  [29,30], NSAID  [31] or 
dextran sulfate sodium (DSS) induced ileitis and colitis models [32].  
Remarkably, animal studies revealed beneficial effects on gastrointestinal damage not only for PC 
but also for selected lysophospholipids. In rats suffering from TNBS induced colitis, rectal application 
of lysophosphatidic acid (LPA) and lysophosphatidylethanolamine (LPE) caused a decreased mucosal 
damage indicated by a reduction in ulcer size and depth  [33]. LPE is derived from 
phosphatidylethanolamine, whereas LPA can be synthesized via different routes, among others from 
lysophosphatidylcholine (LPC). However, in a cell culture model of inflammation, anti-inflammatory 
effects could only be shown for PC and LPC but neither for phosphatidylethanolamine nor for 
sphingomyelin [34–36]. It can therefore be speculated, that different lipid mediators exhibit highly 
specific functions within the pro-inflammatory signaling cascade, thus making a tight regulation of 
lipid metabolism necessary for maintaining homeostasis.  
3. Role of PC in Ulcerative Colitis 
The first evidence that PC might play a role in the pathogenesis of human UC came from lipid 
analysis of mucus gained by gentle scraping of the rectal wall with a cotton wool sponge during 
rectoscopy. Patients suffering from ulcerative colitis in clinical remission, but not from Crohn’s 
disease, showed significantly reduced PC/mg dry weight compared to healthy controls [20]. These 
results were confirmed in patients with active disease [37] as well as by analysis of ileal and colonic Int. J. Mol. Sci. 2010, 11                 
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mucus gained during colonoscopy and compared to total protein levels of the acquired mucus 
aliquots  [21]. Based on these findings, clinical studies were initiated to investigate whether 
supplementation of the missing mucus PC would alleviate the inflammation in UC. Because rectal 
application by a klysma was unsuccessful (patients could not keep the lipid emulsion), PC was 
encapsulated with the polymer Eudragit S to allow a pH dependent release in the terminal ileum, as 
previously used by pharmaceutical companies for a late release of mesalazine [38]. This was necessary 
because, if taken orally, most supplemented PC is absorbed in jejunum. Using Eudragit S encapsulated 
soy lecithin allowed to increase the rectal amount several times above concentrations found in 
otherwise healthy subjects [37]. Proof of principle (Phase IIa/b) studies were conducted by Stremmel 
et al. [37,39,40] and showed a tremendous response. Clinical activity could be reduced in up to 90% of 
patients. Remission could be achieved in up to 50% after a treatment period of three months. A phase 
III study is planned.  
Another hint that PC metabolism plays a role in pathogenesis, is the link between UC and primary 
sclerosing cholangitis (PSC). The occurrence of PSC is rare and its causes are unknown. However, 
PSC is an immunologic disorder and its appearance is often associated with ulcerative colitis. 
Inflammation of the bile ducts results in impaired bile flow from the liver to the duodenum. 
Interestingly, in a colon carcinoma derived cell line, the application of conjugated primary bile salts 
(CPBS) reduced endotoxin permeability through differentiated confluent cells, and decreased the 
production of pro-inflammatory mediators, such as TNF-α, interleukin 6 (IL-6), interleukin 8 (IL-8) 
and interleukin 10 (IL-10). Additional treatment with PC further reduced interleukin levels and 
especially diminished levels of TNF-α [41], thus indicating a synergistic anti-inflammatory action of 
PC and CPBS. Dysfunction in PC metabolism might therefore also play a role in PSC development. 
These findings highlight the relevance of specific phospholipids, especially PC, in gastrointestinal 
inflammation and indicate that PC is one of the important players in the process of chronic intestinal 
inflammation.  
4. Anti-Inflammatory Signaling by PC  
Although the anti-inflammatory properties of PC have been shown in cell culture as well as in 
animal models and humans, the molecular background behind these effects is insufficiently 
understood. However, we hypothesized that in the gut it has two possible functions: 1. It is essential 
for the surface hydrophobicity of the mucus and therefore protects the underlying tissue against 
intraluminal aggressors. 2. Mucus phospholipids might also be integrated into the plasma membranes 
of enterocytes and modulate the signaling state of the mucosa  [34]. The groups of Lenard M. 
Lichtenberger and Brian A. Hills have shown in several publications that surface hydrophobicity 
throughout the GI tract depends on mucus phospholipids [5]. They hypothesized that the positively 
charged polar headgroup of PC electrostatically interacts with the strongly negatively charged mucins, 
forming a monolayer with the fatty acid chains extending luminally (Figure 1). This would form a 
hydrophobic film that expels luminal toxins and bacteria. Hydrophobicity and surface PC 
concentration could indeed be linked in several publications  [5,42,43]. Most interestingly, recent 
experiments on surgical specimens revealed reduced surface tension in UC patients in parallel to a 
decreased PC content [44], which indicates a probable role of this mechanism in pathogenesis of UC. Int. J. Mol. Sci. 2010, 11                 
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However, recent findings further suggest a complex interplay of PC with various mucosal signaling 
pathways, including TNF-α signaling, activation of NF-κB, cytokine expression and the 
mitogen-activated protein kinase (MAPK) pathway, as will be discussed in the following.  
In vitro experiments with latex bead phagosomes, which are internalized by macrophages, allow the 
analysis of phagosome actin assembly. This process is associated with the killing of pathogens, such as 
mycobacteria, that use macrophage phagosomes for intracellular survival within their respective host. 
Actin nucleation was found to be either activated or inhibited after application of various lipids, mostly 
in an ATP dependent manner. The experimental outcome suggested the modulation of the involved 
signaling pathways due to the integration of lipids into the phagosomal membrane [35]. Under any 
conditions, PC displayed inhibitory properties, thus promoting the survival of mycobacteria in 
macrophages [34,35].  At first sight, these results seem to indicate a role for PC in promoting the 
development of a pathologic condition rather than acting in a protective manner. However, this effect 
was due to the blocking of actin assembly, a pro-inflammatory process, which reveals rather 
anti-inflammatory properties of PC application. 
In polarized CaCo2 cells, application of PC either from the apical or basolateral site inhibited the 
phosphorylation and activation of the MAP kinases p38, ERK1 and ERK2. Equally, anti-inflammatory 
effects of PC as well as LPC could be proofed by the downregulation of pro-inflammatory cytokines 
such as IL-8, monocyte chemotactic protein-1 (MCP-1) and interferon γ-inducible protein-10 (PI-10) 
in CaCo2 cells [34]. Furthermore, the dietary supplementation of PC in rats with collagen-induced 
arthritis diminished the activation of leukocytes [2]. It can be speculated, that exogenous or mucus PC 
is integrated into cellular membranes and regulates downstream signaling cascades by altering 
membrane PC content and vertical or lateral distribution within the membrane lipid bilayer. Effects of 
LPC might at least partially be mediated via its conversion to PC [34].   
PC molecules can be transported within cells by the phosphatidylcholine transfer protein 
(STARD2/PCTP) which has also been speculated to have regulatory functions [45]. PCTPs bind their 
substrates via the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) 
domain, which can be found in 15 different human proteins that are involved in the control of lipid 
metabolism. PCTP acts as shuttle from the endoplasmic reticulum to plasma membranes in order to 
provide PC for restocking. STARD10, another member of the STARD2/PCTP family, equally binds 
PC and is assumed to export lipids into the bile. Dysfunction of START proteins has been associated 
with different kinds of disease, also including autoimmune disorders. However, mice lacking PCTP do 
not show a clear phenotype which might be due to a compensatory function of STARD10 [46]. 
Further potential candidates to be involved in PC signaling are members of the peroxisome 
proliferator activated receptor (PPAR) family, ligand activated nuclear receptors that are involved in 
inflammatory processes and lipid metabolism. Exemplarily, PPARγ2 has been shown to prevent 
lipotoxic effects by enhancing the lipid buffering capacity in organs and regulating the expansion of 
adipose tissue [47]. Such a protective role of PPAR family members could be shown not only for 
PPARγ2 but also for PPARα. Drug induced activation of this receptor is already used in order to treat 
human disorders of the lipid metabolism, although its endogenous ligand has not yet been identified. 
However, recent findings suggest 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine to be such an 
endogenous PPARα ligand [48], thus hinting at the involvement of PC species in PPAR activation. It 
is noteworthy, that activators of PPARα had beneficial effects on altered TNF-α levels in patients with Int. J. Mol. Sci. 2010, 11                 
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dyslipidemia [49], which might suggest a new therapeutic target for anti-inflammatory treatment by 
PC application.  
TNF-α, a cytokine with a variety of different functions, has been implicated to play a key role in 
inflammation and is involved in both chronic inflammation and lipid metabolism. It enhances the 
production of free fatty acids, induces lipolysis, regulates lipid metabolism associated enzymes and 
influences cholesterol metabolism. Plasma levels of TNF-α are altered in patients suffering from 
dyslipidemia and can be regulated by drugs interfering with lipid metabolic pathways [49]. In IBD, 
TNF-α levels are increased and associated with mucosal inflammation. Treatment with   
anti-TNF-α-antibodies significantly improved disease activity, which implies a key role for TNF-α in 
pro-inflammatory signaling  [50,51]. Therapeutic application of Infliximab, a chimeric monoclonal 
antibody which binds to TNF-α with high affinity, was shown to be effective not only in the treatment 
of Crohn’s disease but also in UC. TNF-α treatment ameliorated disease activity in patients suffering 
from UC, as shown by the induction of mucosal healing [52], thus pointing out the significant role of 
TNF-α in IBD pathogenesis. 
TNF-α signal transduction has been linked to specialized, liquid ordered areas within cellular 
membranes, termed lipid rafts  [53]. Lipid rafts are dynamic assemblies of lipids, cholesterol and 
proteins which facilitate signal transduction and regulate membrane function. Cholesterol can be found 
throughout rafts whereas sphingolipids are located in the outer exoplasmic leaflet, as opposed to 
phospholipids, that are enriched in the inner cytoplasmic part [54]. In order to form larger platforms, 
single rafts can cluster together which allows improved signaling by the recruitment of adaptor 
molecules. Lipid rafts have been implicated in the compartmentalization of membranes, thus 
generating a heterogenic composition in order to regulate membrane bioactivity [55]. Furthermore, 
lipid rafts seem to play a role in various pathological conditions, such as viral infections and 
Alzheimer’s disease and are involved in immune cell signaling [56].  
Also in TNF-α mediated signaling, lipid rafts are required for a proper signal transduction. For TNF 
receptor 1 (TNFR1), it has been shown that binding of TNF-α induces the translocation of the receptor 
to lipid rafts where a signaling complex is formed by the recruitment of adaptor molecules. Cholesterol 
depletion disrupted lipid rafts and blocked NF-κB activation, thus proving that these specialized 
membrane domains are critical for NF-κB signaling  [57]. The analysis of TNF receptor CD120a 
identified its death domain, not only to be necessary for the induction of either apoptosis or NF-κB 
signaling, but also to be critical for its localization to lipid rafts [58]. The application of exogenous PC 
to CaCo2 cells changed the compartmentation of TNFR1 and TNFR2 to lipid rafts without interfering 
with TNF-α receptor binding [59]. Interestingly, this would implicate activation of NF-κB signaling 
rather than its inhibition. As PC had been shown to display anti-inflammatory properties, it can be 
speculated that alternative regulatory mechanisms must be involved in the downstream signaling 
cascade after TNF receptor binding.  
TNF-α induced NF-κB activation, as a key event in inflammatory signaling, was analyzed in the 
human colon carcinoma cell line CaCo2. Exogenous PC application inhibited NF-κB nuclear 
translocation and activation in a time and dose dependent manner. It can therefore be concluded that 
TNF-α stimulated NF-κB activation, which is one of the key features in pro-inflammatory signaling 
pathways, is influenced by PC. The inhibition was most effective when unsaturated fatty acid side 
chains were present within the PC molecule [34,59], showing the relevance of phospholipid structure Int. J. Mol. Sci. 2010, 11                 
 
 
4157
in modulating intracellular signaling. Interestingly, already in the 1980s, it could be shown that 
patients suffering from UC had increased arachidonic acid content in phospholipids found in the 
inflamed colonic mucosa as compared to healthy controls. Docosahexaenoic acid was also increased, 
whereas levels of oleic acid and palmitoleic acid were reduced [60]. The observed alterations in the 
fatty acid composition were attributed to the colonic inflammation and indicated the arachidonic acid 
metabolism to play a role in UC. 
Taken together, experimental outcomes from cell culture assays, the analysis of animal models as 
well as clinical trials, have demonstrated a positive role of PC in anti-inflammatory signaling by 
targeting key signaling pathways. PC inhibits phagosomal actin nucleation, interferes with MAP 
kinase phosphorylation, and reduces expression levels of pro-inflammatory cytokines. Furthermore, 
TNF receptors are translocated to lipid rafts and activation of NF-κB is diminished by PC treatment, 
resulting in anti-inflammatory signaling.  
5. cPLA2α—A Key Regulator in Inflammatory Signaling Downstream of PC? 
Decreased levels of PC in mucus obtained from UC patients indicate a defect either in PC synthesis 
or secretion. Typically, inflammatory processes of UC start in the rectum, concentrate in the colon and 
with progress of the disease spread towards the coecum. A defect in ileal PC secretion would result in 
a gradual decrease of mucus PC content from the ileum towards the rectum, consistent with a disturbed 
barrier function of the mucus. Thus, epithelial cells in the rectum and colon would be at highest risk to 
be attacked by bacteria which would trigger an inflammatory response. For more information on this 
issue, the interested reader is referred to a recent review which covers this topic in more detail [61]. As 
alterations in mucus PC were observed irrespective of the disease activity, the diminished PC content 
is probably more likely to be a primary cause in UC etiology, rather than a secondary 
phenomenon [21]. However, an alternative or additional explanation for the diminished PC content, 
aside from a reduction in PC secretion, would be the increased degradation of PC by phospholipases. 
As has been previously shown, the arachidonic acid content of PC is increased in the inflamed mucosa 
of patients suffering from ulcerative colitis [60], which indicates a significance of arachidonic acid 
metabolism in IBD etiology. In this regard, attention should be paid especially to the cytosolic 
phospholipase  
A2α (cPLA2α). 
cPLA2α specifically cleaves arachidonic acid from the sn2 position of membrane 
phospholipids [62], thereby releasing an important precursor of the eicosanoid biosynthesis cascade. 
Via calcium binding to the N-terminal C2 domain, a physiologically relevant increase of intracellular 
calcium triggers the translocation of cPLA2α from the cytosol to PC containing membranes, such as 
the Golgi apparatus, the endoplasmic reticulum or the nuclear envelope [62,63]. Phosphorylation of 
serine residues, including the phosphorylation at Ser505 by MAP kinases, is thought to stabilize 
membrane binding of the enzyme and enhance its catalytic activity. The same effect is proposed to be 
mediated by association of cPLA2α with anionic phospholipids as reviewed by Hirabayashi et al. [63]. 
Co-localization of cPLA2 and MAP kinases has been shown in lipid bodies of human leukemic U937 
cells, thereby emphasizing the regulatory function of MAP kinases for cPLA2α activity  [64]. Int. J. Mol. Sci. 2010, 11                 
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Furthermore, the study of ERK1/2, p38 and JNK in a cell culture model revealed that MAP kinases 
contribute to prostaglandin signaling by regulating the release of arachidonic acid [65]. 
Indications of the relevance of cPLA2α function in the gastrointestinal system were obtained by 
mutation of the cPLA2 gene in a mouse model of human familial adenomatous polyposis. The gene 
mutation decreased the size of intestinal polyps, but had no effect on polyps located in the colon [66]. 
In a rat model of TNBS induced colon inflammation, the extracellular PLA2 inhibitor 
carboxymethylcellulose-linked phosphatidylethanolamine (CMPE) improved the disease status and 
reduced the mortality rate [67]. Although this effect is likely to be mediated via the inhibition of 
secretory rather than cytoplasmic PLA2, it outlines the importance of cPLA activity in intestinal 
inflammation in general.  
In human, an adult male with inherited cPLA2α deficiency displayed selective ulceration in ileum 
and jejunum together with gastrointestinal blood loss and dysfunction in eicosanoid production as well 
as significantly reduced arachidonic acid levels in platelet activation [68]. Thus, functional impairment 
or complete loss of cPLA2α function resulted in damage to the gastrointestinal tract. This might 
suggest a specific role for cPLA2α in maintaining the homeostasis and integrity in this part of the 
digestive system. Although the increased degradation of PC by cPLA2α overexpression may mediate 
pro-inflammatory properties, the impaired function of cPLA2α equally causes malfunctions, thus 
hinting at a pro-inflammatory as well as anti-inflammatory role of phospholipases [69]. 
cPLA2α acts through the hydrolysis of membrane phospholipids that release free arachidonic acid 
which are further used for downstream metabolite production. In a CaCo2 cell model, LPC was found 
to increase calcium levels and decrease the transepithelial electrical resistance (TEER) due to altered 
tight-junction permeability  [70]. An impaired TEER facilitates bacterial translocation and might 
therefore contribute to the development and maintenance of inflammatory processes. However, cell 
culture assays also showed a reduced NF-κB activation by LPC treatment [34], indicating a complex 
role for LPC within inflammatory signaling. 
Beside the impact of LPC, arachidonic acid is likely to be a key factor in mediating the effects of 
cPLA2α activity. Arachidonic acid can be processed either via the cyclooxygenase (COX) pathway or 
the lipoxygenase (LOX) pathway, thus leading to the production of lipid mediators that might be 
involved in the pathogenesis of IBD. It is likely, that selective blocking of one pathway redirects 
arachidonic acid metabolism to the alternative pathway, which might be an explanation for the 
induction of gastrointestinal damage by NSAID meditated COX inhibition. Simultaneous blocking of 
both pathways showed good anti-inflammatory effects and reduced gastrointestinal toxicity [71]. 
Synthesis of arachidonic acid is the rate limiting step in prostaglandin production [62] via the COX 
pathway. Prostaglandins, especially prostaglandin E2 (PGE2), have been shown to exhibit 
gastroprotective mechanisms: Intragastric injection of rats with PGE2 resulted in enhanced 
phospholipid levels in the gastric mucosa, an effect which was most prominent for PC  [4]. 
Furthermore, prostaglandins increased the gastric surface hydrophobicity and stimulated lipid 
biosynthesis (reviewed by Lichtenberger [5]). The parenteral administration of NSAIDs in healthy rat 
caused decreased hydrophobicity of the gastric and duodenal mucosa. This effect could be linked to 
defects in prostaglandin generation in addition to which the involvement of other factors is likely [7]. 
Prostaglandins have not only been implicated in gastrointestinal inflammation but they also seem to 
play a role in colon tumor development. Colon cancer cell lines specifically showed increased levels of Int. J. Mol. Sci. 2010, 11                 
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PGE2 and COX2 when cultured in a hypotonic environment as opposed to cell lines derived from 
non-tumor intestinal epithelial cell lines [65]. An analysis of eight colorectal cancer cell lines and 65 
colorectal cancers showed an overexpression of cPLA2 in about 50% of the cases which correlated 
with COX2 expression in a positive manner [72]. 
Taken together, experimental findings show the involvement of cPLA2α in the regulation of various 
pathological conditions, its effect resulting from the degradation of membrane PC. Pro-inflammatory, 
as well as anti-inflammatory properties of cPLA2α, indicate the need for a tight regulation of its 
function, which has to be taken into account when addressed as a therapeutic target. For this reason, 
not complete inhibition but rather a reduction in activity to basal levels might be the best method of 
choice [69].  
6. Perspectives 
The development of ulcerative colitis, an autoaggressive, chronic inflammatory bowel disease, can 
be attributed to a misbalanced inflammatory response to luminal pathogens within the gastrointestinal 
system. Although the underlying signaling mechanisms remain incompletely understood, it has been 
shown that PC plays an important role in establishing a protective mucosal barrier as an essential part 
of the intestinal mucus. Furthermore, PC might be integrated into phospholipid membranes of 
enterocytes, thereby altering downstream signaling cascades. The exogenous application of PC in 
patients suffering from ulcerative colitis, ameliorated clinical parameters and acted in an 
anti-inflammatory manner. Beneficial effects of PC treatments were also evident in animal models of 
(chronic) inflammatory diseases.  
PC increases hydrophobicity on the luminal surface of the GI-tract, inhibits actin nucleation, TNF-α 
mediated NF-κB nuclear translocation, MAP kinase activation and pro-inflammatory cytokine 
expression. It might translocate TNF receptors to lipid rafts, influencing eicosanoid production via 
interaction with cPLA2α. Light has been shed on a variety of possible PC dependent pathways, 
suggesting that it is required to “fine tune” the complex signaling network which regulates 
inflammatory processes. Although many open questions remain to be solved, the presently available 
data strongly encourage further investigations of PC involvement in inflammation. It is tempting to 
speculate that the modulation of PC dependent signaling might in future be highly relevant in 
establishing new therapies for IBD treatment, especially ulcerative colitis. 
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